moderate - Elective ophthalmic procedures exhibit some economic sensitivity as patients may defer non-urgent glaucoma surgery during recessions, though disease progression creates clinical urgency limiting deferral periods. Cataract surgery volumes (where iStent is often combined) show modest GDP correlation as seniors prioritize vision restoration. However, Medicare coverage (majority of glaucoma patients are 65+) provides revenue stability versus purely commercial insurance markets. Economic downturns impact ASC utilization rates and physician practice economics, potentially slowing adoption of premium MIGS devices.

Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for pre-profitable growth companies, particularly impacting P/S multiples currently at 13.5x; (2) Increased borrowing costs affect hospital and ASC capital budgets for equipment purchases; (3) Rate-driven market volatility reduces risk appetite for cash-burning businesses with 4+ year profitability timelines. With 0.16x debt/equity and strong 4.69x current ratio, Glaukos faces minimal direct financing risk but significant valuation multiple compression in rising rate environments.

growth - Attracts growth-oriented investors willing to accept near-term losses for long-term market opportunity in $4-5B addressable MIGS market. The 32.3% revenue growth rate, innovative technology platform, and demographic tailwinds (aging population) appeal to investors seeking exposure to minimally invasive surgical trends. Recent 30.6% three-month return reflects momentum trading around pipeline milestones and sector rotation into healthcare innovation. Not suitable for value or income investors given negative earnings, no dividend, and premium 13.5x P/S valuation requiring sustained high growth to justify.